Clinical Trials · NCT07850921
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
- Phase
- Phase 1/Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Enrollment
- 192
- Start date
- Jun 2027
- Locations
- See registry
- Primary endpoint
- Occurrence of Treatment Emergent Adverse Events (TEAEs)